Maleimidopropionic Acid CJC-1295 vs PNC-27: Chemical Structure, GHRH Kinetics, and Comparative Protocols

This comparative technical analysis examines the structural role of maleimidopropionic acid in CJC-1295, its impact on pharmacokinetic half-life, and how GHRH receptor agonists differ from cytolytic research peptides like PNC-27. Designed for laboratory investigators, this guide outlines analytical purity standards, reconstitution parameters, and receptor-binding mechanisms for in vitro and preclinical research.

GMP-compliant U.S. facilities
ISO 17025 third-party COAs
100% domestic — no imports
Fast tracked domestic shipping
Shop research peptides

Quick answer

This comparative technical analysis examines the structural role of maleimidopropionic acid in CJC-1295, its impact on pharmacokinetic half-life, and how GHRH receptor agonists differ from cytolytic research peptides like PNC-27. Designed for laboratory investigators, this guide outlines analytical purity standards, reconstitution parameters, and receptor-binding mechanisms for in vitro and preclinical research.

Reviewed by PX1 Research scientific team

Key takeaways

  • Maleimidopropionic acid (also referred to in chemical literature as maleimidoproprionic acid) is the specific chemical linker incorporated into [CJC-1295](/research-peptides/cjc-1295-no-dac) to form the Drug Affinity Complex (DAC).
  • To evaluate metabolic stability in experimental models, researchers frequently contrast [CJC-1295 with DAC](/product/cjc-1295-with-dac) against [CJC-1295 No DAC](/product/cjc-1295-no-dac).
  • PNC-27 is a synthetic 32-amino-acid chimeric peptide consisting of an HDM-2-binding domain (residues 12-26 of p53) attached to a cell-penetrating transmembrane domain (penetratin).
  • Understanding the divergence between GHRH analogs containing maleimidopropionic acid and membrane-active peptides like PNC-27 is essential when designing experimental assays.

Maleimidopropionic Acid in CJC-1295: Structural Function and Core Differences

Maleimidopropionic acid (also referred to in chemical literature as maleimidoproprionic acid) is the specific chemical linker incorporated into CJC-1295 to form the Drug Affinity Complex (DAC). This linker allows the peptide to form a covalent thioether bond with circulating serum albumin at the Cys34 residue, extending its plasma elimination half-life from approximately 30 minutes to over 6 days in animal models. In contrast, CJC-1295 No DAC (Modified GRF 1-29) lacks this maleimidopropionic acid moiety, resulting in rapid clearance and short-acting pulsatile growth hormone stimulation.

When comparing GHRH analogs to distinct oncology research molecules such as PNC-27, the functional mechanism changes completely. While CJC-1295 (with or without DAC) interacts with the growth hormone-releasing hormone receptor (GHRHR) to evaluate Somatotrophic signaling, PNC-27 is a membrane-active peptide engineered to bind HDM-2 proteins on transformed cell membranes, causing targeted cell lysis in cell culture assays.

CJC-1295 With DAC vs. CJC-1295 No DAC: Pharmacokinetic Dynamics

To evaluate metabolic stability in experimental models, researchers frequently contrast CJC-1295 with DAC against CJC-1295 No DAC. Both compounds share an identical 29-amino-acid backbone modeled after the N-terminal sequence of native GHRH (1-29), featuring four specific amino acid substitutions (D-Ala2, Gln8, Ala15, and Leu27) designed to resist enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV).

The sole structural differentiator lies in the addition of maleimidopropionic acid conjugated via a Lysine linker at position 30 in the DAC variant. Without maleimidopropionic acid, CJC-1295 No DAC exhibits a half-life of roughly 15 to 30 minutes in vivo, making it suitable for models examining acute, pulsatile growth hormone (GH) release. Conversely, the presence of maleimidopropionic acid enables continuous, basal elevation of GH and downstream insulin-like growth factor 1 (IGF-1) levels over extended sampling intervals.

PNC-27 Mechanism of Action: Membrane Lysis and HDM-2 Binding

PNC-27 is a synthetic 32-amino-acid chimeric peptide consisting of an HDM-2-binding domain (residues 12-26 of p53) attached to a cell-penetrating transmembrane domain (penetratin). In preclinical oncology research, PNC-27 is studied for its ability to selectively target and disrupt the cell membranes of cancer cells while sparing non-transformed cell lines.

In vitro assays indicate that PNC-27 selectively binds to HDM-2 membrane proteins expressed on malignant cell surfaces, inducing pore formation, loss of membrane integrity, and rapid necrosis. Unlike growth hormone secretagogues that stimulate G-protein coupled receptors (GPCRs) to alter gene expression and protein synthesis, PNC-27 acts as a direct physical disruptor of transmembrane architecture, serving as a reference compound in membrane-permeabilization studies.

Comparative Analysis: GHRH Pathway Agonists vs. Cytolytic Peptides

Understanding the divergence between GHRH analogs containing maleimidopropionic acid and membrane-active peptides like PNC-27 is essential when designing experimental assays. The following points summarize the primary biochemical distinctions observed in preclinical investigations:

1. Receptor Target: CJC-1295 selectively binds to the GHRH receptor on anterior pituitary cells, triggering intracellular cyclic AMP (cAMP) accumulation. PNC-27 targets membrane-bound HDM-2 complexes without initiating classical GPCR cascades. 2. Downstream Effects: GHRH agonists evaluate systemic endocrine responses, tissue repair markers, and IGF-1 gene expression. PNC-27 evaluates cell lysis, lactate dehydrogenase (LDH) release, and membrane permeability in tumor cell assays. 3. Modification Role: Maleimidopropionic acid in CJC-1295 serves exclusively as a bioconjugation anchor for albumin binding to prolong systemic presence, whereas the penetratin domain in PNC-27 functions as a membrane-traversing structural peptide.

In multi-pathway investigation frameworks, laboratories often utilize GHRH agonists alongside complementary secretagogues such as Ipamorelin or Sermorelin to map pituitary receptor synergy, while keeping cytotoxic peptides like PNC-27 isolated to separate cell-line viability studies.

Quality Verification: Analytical Standards for Maleimidopropionic Acid CJC-1295

Synthetic peptides containing reactive functional groups like maleimidopropionic acid require rigorous quality control to prevent premature cross-linking or hydrolytic cleavage during synthesis and storage. PX1 Research enforces strict analytical protocol validation across every batch.

Each lot undergoes Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm peptide purity exceeds 99%. Mass Spectrometry (ESI-MS) confirms the exact molecular weight, verifying the intact structure of the maleimidopropionic acid linker. Furthermore, mandatory chromogenic LAL assays ensure bacterial endotoxin levels remain strictly below <0.01 EU/mg, protecting cell cultures from non-specific inflammatory artifacts during in vitro assays.

Laboratory Reconstitution and Handling Parameters

Lyophilized CJC-1295 (with or without maleimidopropionic acid) and PNC-27 require controlled reconstitution techniques to maintain structural stability. Reconstitution should be conducted in a laminar flow hood using sterile bacteriostatic water or sterile 0.9% sodium chloride solution depending on experimental assay specifications.

To minimize mechanical shear stress during reconstitution, diluent should be introduced slowly down the vial's glass wall and gently swirled. Vortexing or aggressive shaking must be avoided to prevent peptide aggregation. For detailed protocols on reconstitution volumes and molar calculations, investigators can refer to the comprehensive PX1 Research Library.

Storage and Stability Specifications for Research Compounds

Lyophilized vials of maleimidopropionic acid CJC-1295 and PNC-27 should be stored at -20°C in a dry environment protected from light exposure, where they remain stable for up to 24 months. After reconstitution, stock solutions should be aliquot-frozen at -80°C to avoid freeze-thaw cycles, which degrade peptide structural integrity.

Reconstituted liquid aliquots stored at 2°C to 8°C should be utilized within 14 to 21 days for optimal assay repeatability. Facilities requiring high-volume supplies for long-term longitudinal research can explore custom supply arrangements through the PX1 wholesale lab account program.

Peptide Comparison Matrix: CJC-1295 Variants, PNC-27, and Class Agonists

To assist laboratory personnel in selecting the appropriate reference standard, the table below highlights key chemical characteristics across related compounds in our catalog of high-purity research compounds:

• CJC-1295 with DAC: Contains maleimidopropionic acid linker; binds serum albumin; extended 6-8 day half-life; GHRH receptor agonist. • CJC-1295 No DAC: Modified GRF 1-29 without linker; rapid clearance (~30 min half-life); natural pulsatile GHRH modeling. • PNC-27: 32-amino-acid cytolytic peptide; contains p53/HDM-2 binding domain; causes selective cell membrane lysis in oncology assays. • Tesamorelin: Hexenoyl-modified GHRH analog; studied for pituitary stimulation and lipid metabolism assays Tesamorelin. • GHRP-2: Synthetic ghrelin mimetic; acts on growth hormone secretagogue receptor (GHS-R1a) GHRP-2.

Supply Chain Quality Assurance and USA Manufacturing Standards

PX1 Research manufactures all research compounds within state-of-the-art, GMP-compliant facilities located in the United States. Analytical testing is conducted by independent ISO 17025 accredited laboratories to guarantee batch-to-batch consistency and raw material authenticity.

Every shipment includes a lot-specific Certificate of Analysis (COA) featuring raw RP-HPLC chromatograms and mass spectra data. Orders dispatch same-day when placed before 2 PM PST, shipping directly from our California and Arizona logistics hubs to preserve product integrity during transit.

Frequently Asked Questions

What is the function of maleimidoproprionic acid in CJC-1295?

Maleimidopropionic acid (also spelled maleimidoproprionic acid) is a chemical bioconjugation linker attached to CJC-1295. It covalently binds to circulating serum albumin in animal models, extending the peptide's metabolic half-life from ~30 minutes to over 6 days.

How does CJC-1295 No DAC differ from maleimidopropionic acid CJC-1295?

CJC-1295 No DAC lacks the maleimidopropionic acid (DAC) linker. Consequently, CJC-1295 No DAC is rapidly cleared by the kidneys and DPP-IV enzymes, making it ideal for studying pulsatile growth hormone release rather than continuous elevation.

What is the key mechanism difference between CJC-1295 and PNC-27?

CJC-1295 is a GHRH receptor agonist that activates endocrine signaling pathways (GH/IGF-1 axis). PNC-27 is a cytolytic peptide that targets HDM-2 membrane proteins on malignant cell membranes to induce selective pore formation and cell lysis in oncology models.

Why is maleimidopropionic acid CJC-1295 used in tissue repair research?

Preclinical studies suggest that extended GHRH receptor activation by CJC-1295 with DAC leads to sustained elevations in circulating IGF-1, a key mediator studied in collagen synthesis, cellular proliferation, and tissue repair models.

What analytical methods verify the presence of maleimidopropionic acid in CJC-1295?

Electrospray Ionization Mass Spectrometry (ESI-MS) verifies the exact molecular weight shift corresponding to the maleimidopropionic acid moiety, while RP-HPLC confirms peptide purity exceeds 99%.

What endotoxin standards apply to PX1 CJC-1295 and PNC-27 lots?

All PX1 Research compounds are tested using chromogenic LAL assays to ensure endotoxin levels remain below <0.01 EU/mg, preventing non-specific cellular reactions in laboratory assays.

How should CJC-1295 with maleimidopropionic acid be reconstituted for laboratory use?

Reconstitute using sterile bacteriostatic water or sterile 0.9% saline under sterile laminar flow conditions. Direct liquid down the vial wall and swirl gently without vortexing to avoid protein denaturation.

What are the recommended storage conditions for PNC-27 and CJC-1295?

Store lyophilized vials at -20°C protected from light. Once reconstituted, store short-term liquid stock at 2°C to 8°C for up to 21 days, or aliquot and freeze at -80°C for long-term storage.

Can CJC-1295 No DAC and PNC-27 be evaluated in the same cell assay?

Because CJC-1295 No DAC stimulates GHRH receptor pathways and PNC-27 acts as a membrane-disrupting cytotoxic agent, combining them in a single assay would lead to conflicting biological signals unless specifically testing cytolytic resistance under endocrine stimulation.

Where are PX1 research peptides manufactured and shipped from?

PX1 Research compounds are manufactured in US-based GMP-compliant facilities and shipped same-day (Monday through Friday) from fulfillment centers located in California and Arizona.

Related pages

All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.